ERBB2 and neoplasm: Excluding 42 patients whose hormone receptor status was not clearly identified, the data for this study included 253 HR-positive, HER2-negative tumors (41.6%), 204 HER2-positive cases (33.6%), and 172 TNBC (28.3%), which means the distribution of tumor subtypes in the collected data was well-balanced.